NASDAQ:SRNE - Sorrento Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.26 -0.07 (-3.00 %) (As of 02/19/2019 04:00 PM ET)Previous Close$2.33Today's Range$2.24 - $2.3952-Week Range$1.95 - $10.65Volume984,000 shsAverage Volume1.33 million shsMarket Capitalization$276.35 millionP/E Ratio17.38Dividend YieldN/ABeta2.51 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company is focusing on the development of chimeric antigen receptor (CAR)-based immunotherapies using autologous T-cells. It is developing CD38 Directed CAR-T, a cellular therapy used for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; CD123 Directed CAR-T for the treatment of acute myelogenous leukemia; and human antibodies, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT, and CD137. The company is also developing intracellular targeting antibodies comprising STAT3, Mutant KRAS, MYC, p53, and TAU to modulate the evolution of cancer, inflammation, autoimmune diseases, diabetes, central nervous system diseases, cardiovascular diseases, and viral infections; and oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. In addition, it offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company has a licensing agreement with Mabtech Limited to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California. Receive SRNE News and Ratings via Email Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRNE Previous Symbol CUSIPN/A Webwww.sorrentotherapeutics.com Phone858-203-4100Debt Debt-to-Equity Ratio0.65 Current Ratio1.76 Quick Ratio1.76Price-To-Earnings Trailing P/E Ratio17.38 Forward P/E Ratio-1.31 P/E GrowthN/A Sales & Book Value Annual Sales$151.86 million Price / Sales1.82 Cash Flow$0.1932 per share Price / Cash Flow11.70 Book Value$2.50 per share Price / Book0.90Profitability EPS (Most Recent Fiscal Year)$0.13 Net Income$9.13 million Net Margins-303.77% Return on Equity-45.28% Return on Assets-22.07%Miscellaneous Employees162 Outstanding Shares122,280,000Market Cap$276.35 million OptionableOptionable Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions What is Sorrento Therapeutics' stock symbol? Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE." When is Sorrento Therapeutics' next earnings date? Sorrento Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 15th 2019. View Earnings Estimates for Sorrento Therapeutics. What price target have analysts set for SRNE? 3 brokers have issued 12-month price targets for Sorrento Therapeutics' stock. Their forecasts range from $10.00 to $40.00. On average, they expect Sorrento Therapeutics' stock price to reach $21.4167 in the next twelve months. This suggests a possible upside of 847.6% from the stock's current price. View Analyst Price Targets for Sorrento Therapeutics. What is the consensus analysts' recommendation for Sorrento Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sorrento Therapeutics. What are Wall Street analysts saying about Sorrento Therapeutics stock? Here are some recent quotes from research analysts about Sorrento Therapeutics stock: 1. According to Zacks Investment Research, "Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and infectious disease. Sorrento Therapeutics, Inc. is based in San Diego, California. " (2/2/2019) 2. HC Wainwright analysts commented, "We ascribe a value of $6.4B based on a sum- of-the-parts approach, or a price per share of $40.00, assuming 159M projected shares outstanding as of end-2Q 2019. The projected share count assumes conversion of all outstanding convertible notes and exercise of all outstanding options and warrants." (9/20/2018) Has Sorrento Therapeutics been receiving favorable news coverage? News articles about SRNE stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sorrento Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future. Who are some of Sorrento Therapeutics' key competitors? Some companies that are related to Sorrento Therapeutics include Intrexon (XON), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International (DYAI), HedgePath Pharmaceuticals (HPPI), BIOQUAL (BIOQ), Vitality Biopharma (VBIO), Cleveland BioLabs (CBLI), Bioanalytical Systems (BASI), US Stem Cell (USRM) and Protalex (PRTX). Who are Sorrento Therapeutics' key executives? Sorrento Therapeutics' management team includes the folowing people: Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 55)Dr. Jerome Bernard Zeldis, Chief Medical Officer & Pres of Clinical Devel. (Age 69)Mr. George K. Ng, Corp. Sec. (Age 45)Mr. Jiong Shao M.B.A., CFA, Exec. VP & CFO (Age 51)Ms. Deborah H. Telman, Sr. VP & Gen. Counsel Who are Sorrento Therapeutics' major shareholders? Sorrento Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.19%), Northern Trust Corp (1.03%), Geode Capital Management LLC (0.86%), D. E. Shaw & Co. Inc. (0.73%), Citigroup Inc. (0.72%) and Bank of New York Mellon Corp (0.35%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, George K Ng, Henry Ji, Jaisim Shah and Pacific Medtech (Bvi) Ltd Asia. View Institutional Ownership Trends for Sorrento Therapeutics. Which major investors are selling Sorrento Therapeutics stock? SRNE stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, MetLife Investment Advisors LLC and Principal Financial Group Inc.. View Insider Buying and Selling for Sorrento Therapeutics. Which major investors are buying Sorrento Therapeutics stock? SRNE stock was acquired by a variety of institutional investors in the last quarter, including Citigroup Inc., BlackRock Inc., Virtus ETF Advisers LLC, Geode Capital Management LLC, Rhumbline Advisers, Bank of New York Mellon Corp, Metropolitan Life Insurance Co. NY and Barclays PLC. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Abg Management Ltd, George K Ng, Henry Ji and Jaisim Shah. View Insider Buying and Selling for Sorrento Therapeutics. How do I buy shares of Sorrento Therapeutics? Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sorrento Therapeutics' stock price today? One share of SRNE stock can currently be purchased for approximately $2.26. How big of a company is Sorrento Therapeutics? Sorrento Therapeutics has a market capitalization of $276.35 million and generates $151.86 million in revenue each year. The biopharmaceutical company earns $9.13 million in net income (profit) each year or $0.13 on an earnings per share basis. Sorrento Therapeutics employs 162 workers across the globe. What is Sorrento Therapeutics' official website? The official website for Sorrento Therapeutics is http://www.sorrentotherapeutics.com. How can I contact Sorrento Therapeutics? Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected] MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 418 (Vote Outperform)Underperform Votes: 211 (Vote Underperform)Total Votes: 629MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: How Does the Quiet Period Work?